1 row is stored for this page
| Field | Field type | Value |
|---|
| generic | String | Sumatriptan (succinate) |
| brand | String | Imitrex (oral, injectable, nasal), Tosymra (nasal spray), Onzetra Xsail (nasal powder), Zembrace SymTouch (low-dose autoinjector), Sumavel DosePro (needle-free SC) |
| structure | File | |
| classes | List of String, delimiter: , | [[:Category:Triptans|Triptan (5-HT1B/1D agonist)]] • [[:Category:Antimigraine medicines|Antimigraine medicine]] • [[:Category:Analgesics|Analgesic]] |
| mechanism | String | |
| uses | String | '"`UNIQ--vote-00000013-QINU`"', '"`UNIQ--vote-00000014-QINU`"' |
| starting_dose | String | Oral: 50-100 mg at migraine onset, may repeat in 2 hours if needed. SC: 6 mg, may repeat in 1 hour. Nasal: 5-20 mg per nostril, may repeat in 2 hours |
| preparations | String | Oral tablets 25, 50, 100 mg; SC injection 4, 6 mg autoinjector; needle-free SC 6 mg (Sumavel); nasal spray 5, 20 mg; nasal powder 22 mg (Onzetra Xsail); low-dose autoinjector 3 mg (Zembrace SymTouch) |
| fda_max | String | 200 mg/day (oral); 12 mg/day (SC); 40 mg/day (nasal spray); 44 mg/day (Onzetra) |
| pill_id | Text | |
| routes | List of String, delimiter: , | Oral • subcutaneous • intranasal |
| onset | String | 10 minutes (SC); 15-30 minutes (nasal); 30-60 minutes (oral) |
| duration | String | 2-4 hours; headache recurrence rate ~20-30% within 24 hours |
| halflife | String | 2 hours'"`UNIQ--ref-00000015-QINU`"' |
| bioavailability | String | ~14% (oral; substantial first-pass); ~97% (subcutaneous); ~17% (nasal)'"`UNIQ--ref-00000016-QINU`"' |
| pregnancy | String | Limited human data; pregnancy registry data have been broadly reassuring relative to baseline malformation rates.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> |
| legal | String | [[USLegal:Prescription only|Rx-only]] in US |
